Pharma News

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study.

Pancreatic cancer often lurks as a silent disease. With no known symptoms, it can progress undetected and spread to other organs.

According to the National Cancer Institute, more than 60,000 Americans will be diagnosed with pancreatic cancer this year, and only about 1 in 10 of those diagnosed will survive the next five years.  The disease ranks as the third leading cause of cancer deaths in the U.S. because it is rarely detected in the early stages when treatment options are most effective.

Lupin Biotech manufacturing facility in Pune receives 17 observations after prior approval inspection by US FDA.

The Company does not believe that the 483 letter will have an impact on the existing revenues from operations of this facility.

The U.S. FDA conducted a Prior-Approval Inspection at Lupin’s Biotech manufacturing facility in Pune, India in October 2022. The inspection concluded with the issuance of a Form 483 with seventeen observations.

Lupin signs an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. (Sunovion) for a purchase price of around USD 75 million, which is more than 600 crores in Indian rupees.

Inhalation portfolio of Lupin expands in the US with these acquisitions of Brovana and Xopenex HFA.

During brain development, neurons have to migrate long distances through complex environments until they reach their final destination. In order to find guidance, they must establish several interactions —which are still hard to study— between their receptors and the surrounding molecules.

The 2012 EU Bioeconomy Strategy is delivering on key actions and has seen a two-fold increase in EU R&I funding for the bioeconomy under Horizon 2020, today Horizon Europe.

GSK plc announced that the US Food and Drug Administration has approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option.

Union Minister of Health and Family Welfare, Dr Mansukh Mandaviya today chaired a meeting with public health experts and officials to review the COVID19 pandemic situation in the country, status of vaccination drive and the Global scenario of new variants of Covid-19.Dr. V K Paul, Member (Health) NITI Aayog was also present during the meeting.

Hetero announced the acquisition of a brownfield manufacturing plant at Penjerla located in Telangana from Johnson & Johnson.

The facility spread across 55.27 acres, will be Hetero’s flagship sterile pharmaceutical and biologics manufacturing unit, bolstered by state-of-the-art technology.